Acumen pharmaceuticals appoints derrell porter, m.d., to its board of directors

Charlottesville, va. and carmel, ind., jan. 04, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for alzheimer's disease (ad), today announced derrell porter, m.d., has joined its board of directors.
ABOS Ratings Summary
ABOS Quant Ranking